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Summary
We showed recently that M3 muscarinic acetylcholine receptor (M3R)-reactive CD3
1 T cells play a pathogenic role in the development of murine autoimmune sialadenitis (MIS), which mimics Sj€ ogren's syndrome (SS). The aim of this study was to determine the effectiveness and mechanism of action of retinoic acid-related orphan receptor-gamma t (RORgt) antagonist (A213) in MIS. Splenocytes from M3R knockout (M3R mice (post-transfer treatment) were treated with A213 every 3 days. Salivary volume, severity of sialadenitis and cytokine production from M3R peptidestimulated splenocytes and lymph node cells were examined. Effects of A213 on cytokine production were analysed by enzyme-linked immunosorbent assay (ELISA) and on T helper type 1 (Th1), Th17 and Th2 differentiation from CD4 1 T cells by flow cytometry. Pretransfer A213 treatment maintained salivary volume, improved MIS and reduced interferon (IFN)-g and interleukin (IL)-17 production significantly compared with phosphatebuffered saline (PBS) (P < 0Á05). These suppressive effects involved CD4 1 T cells rather than CD11c 1 cells. Post-transfer treatment with A213 increased salivary volume (P < 0Á05), suppressed MIS (P < 0Á005) and reduced IFN-g and IL-17 production (P < 0Á05). In vitro, A213 suppressed IFN-g and IL-17 production from M3R-stimulated splenocytes and CD4 1 T cells of immunized M3R -/-mice (P < 0Á05). In contrast with M3R specific responses, A213 suppressed only IL-17 production from Th17 differentiated CD4 1 T cells without any effect on Th1 and Th2 differentiation in vitro.
Introduction
Sj€ ogren's syndrome (SS) is an autoimmune disease in which both autoreactive CD4 1 T cells and activated B cells play important pathogenic roles, and is characterized by lymphocytic infiltration into various organs including exocrine glands, such as salivary and lacrimal glands [1, 2] . The clinical manifestations of SS are categorized into glandular (dry mouth and dry eyes) and extraglandular (other organ disease) involvement [1, 2] .
Although corticosteroids, immunosuppressants and certain biologicals, such as rituximab, are effective for extraglandular manifestations of SS, the usefulness of these drugs against glandular manifestations has not been established [3] . At present, palliative therapies, such as eye drops and secretagogues, are used commonly for dryness of SS [3] . Therefore, there is a need for new therapies for both the glandular and extra-glandular manifestations of SS acting that are based on inhibition of specific pathological process of SS. T helper cells that produce interleukin (IL)-17 [T helper type 17 (Th17) cells] are implicated in the pathology of several autoimmune diseases, including SS, in addition to multiple sclerosis (MS) and rheumatoid arthritis (RA) [4] [5] [6] . IL-17 is known to enhance inflammatory processes. The discovery of Th17 cells as critical mediators of autoimmune disorders provided a unique opportunity to develop new therapeutic strategies that target inhibition of these cells. The nuclear receptor retinoic acid receptorrelated orphan receptor gt (RORgt) plays an indispensable role in the differentiation of Th17 cells [7] [8] [9] [10] , and several synthetic ligands, which bind to and inhibit RORgt (RORgt antagonists), have been developed in recent years [11, 12] . RORgt antagonism seems a promising therapeutic strategy against Th17-mediated autoimmune disorders, acting by the suppression of differentiation and function of Th17 cells [11, 12] .
We have established previously a new murine SS model, in which autoreactive CD3
1 T cells against M3 muscarinic acetylcholine receptor (M3R) play critical roles in the development of sialadenitis (M3R-induced sialadenitis; MIS) [13] . M3R is expressed in exocrine glands, including salivary and lacrimal glands, and plays crucial roles in secretion [14] . Recent studies have focused on M3R as a candidate autoantigen in SS [15] [16] [17] [18] [19] . Interestingly, both interferon (IFN)-g and IL-17 are required for induction of SS-like sialadenitis in MIS [20, 21] , indicating that M3R-reactive Th1 and Th17 cells contribute to the pathogenesis of autoimmune sialadenitis. Thus, MIS might be an ideal model to analyse the effectiveness of RORgt antagonists.
Preliminary data indicate that A213, a potent and selective antagonist of RORgt, inhibits Th17 cell differentiation from CD4
1 T cells in vitro (Sano et al., personal communication). Moreover, A213 inhibited skin inflammation in the murine psoriasis model successfully by suppressing IL-17 production and Th17 cells (Sano et al., personal communication). However, to the best of our knowledge, there was neither evidence concerning the treatment effect of A213 on patients with SS nor ongoing studies.
The present study is a critical assessment of RORgt antagonism as a new therapeutic strategy in SS. Specifically, we determined the effectiveness and mechanism(s) of action of A213 in MIS. We also investigated the suppressive effects of A213 on cytokine production from M3R-reactive T cells. A213 was administered orally in one of two ways: immunized M3R -/-mice (pretransfer treatment) or M3R -/-!Rag-1 -/-mice (post-transfer treatment) every 3 days. Pretransfer treatment with A213 for MIS had minor inhibitory effects on salivary function and sialadenitis. A213 suppressed both M3R-reactive Th1-producing IFN-g and Th17-producing IL-17 against M3R peptide stimulation between immunized M3R -/-mice treated with A213 and placebo. Post-transfer treatment with A213 for MIS inhibited significantly the decrease in saliva secretion and sialadenitis through the suppression of both M3R-reactive Th1 and Th17 cells. The results showed that A213 suppressed immune-mediated pathology, including Th1 and Th17 cells both in vitro and in vivo, and inhibited salivary dysfunction and sialadenitis successfully in MIS through the suppression of IFN-g and IL-17 production. The findings suggest that inhibition of RORgt is a potentially useful therapeutic strategy for SS through the induction of Th1 and Th17 cell-based immune responses. ) were purchased from Charles River Laboratory (Yokohama, Japan). Rag1 -/-mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). M3R knockout mice (M3R -/-), generated from B6 mice, were kindly provided by Dr Matsui (Fureai Higashitotsuka Hospital, Kanagawa, Japan) [22] . All mice were maintained under specific pathogen-free conditions at the Laboratory Animal Resource Center. All experiments were performed according to the Guide for the Care and Use of Laboratory Animals at University of Tsukuba.
Materials and methods

Mice
Synthesized peptides encoding M3R extracellular regions
Six types of peptides that encoded murine M3R extracellular domains -N-terminus 1 (MTLHSNSTTSPLFPNISSS WVHSPSEAGLP, N1), N-terminus 2 (VHSPSEAGLPLGT VSQLDSYNISGTSGNFS, N2), N-terminus 3 (NISQTSGN FSSNDTSSDPLGGHTIWQV, N3), first extracellular loop (FTTYIIMNRWALGNLACDLW, 1st), second extracellular loop (QYFVGKRTVPPGECFIQFLSEP, second) and third extracellular loops (VLVNTFCDSCIPKTYWNLGY, third) -were synthesized chemically by a solid-phase procedure and purified by high-performance liquid chromatography (AnyGen, Gwangju, Korea).
Induction of M3R-induced sialadenitis (MIS)
M3R
-/-mice (male, aged 8-12 weeks) were immunized intradermally at the base of the tail with an emulsified mixture containing six M3R extracellular peptides (20 lg each), Freund's incomplete adjuvant (IFA) and inactivated Mycobacterium tuberculosis (250 lg). Furthermore, 500 ng of Pertussis toxin was injected intraperitoneally on the day of immunization. The same immunization with intradermal injection of the same emulsified mixture was repeated on day 10 after the first immunization. On day 20, splenocytes were isolated from the immunized M3R -/-mice and suspended in phosphate-buffered saline (PBS). Then, 1Á0 3 10 7 of these splenocytes were injected intravenously into the recipient adult Rag1 -/-mice (male, aged 10-14 weeks)
). Analysis of Rag1 -/-mice was conducted on day 45 after transfer ( Fig. 1a ).
Treatment protocol with A213
A213 was kindly provided by Daiichi-Sankyo Company. The chemical structure of A213 is shown in Fig. 1b . The compound was dissolved in PBS at 30 mg/ml, and immunized M3R -/-mice or M3R
-/-!Rag-1 -/-mice received 300 mg/kg of A213 (10 ll/g body weight) or vehicle (PBS, 10 ll/g body weight of mice) orally every 3 days (Fig. 1c) . Treatment commenced on day 1 after the first immunization (protocol A in Fig. 1c , pretransfer treatment) and on day 7 after intravenous injection of splenocytes into M3R
-/- 
Measurement of salivary volume
Mice were first anaesthetized with intraperitoneal injection of pentobarbital (1Á0 mg/kg), then injected subcutaneously with pilocarpine (25 mg/kg). We collected saliva from the oral cavity over a period of 15 min using a 200 ll micropipette. The volume of the sample was measured and expressed relative to body weight. Changes in saliva volume were calculated relative to the volume measured at baseline, using the formula [day-45 saliva volume (ml)/weight (g)]/ [day-0 saliva volume (ml)/weight (g)].
Histopathological analysis
Tissue specimens of salivary glands were embedded in optimal cutting temperature (OCT) compound (Sakura, Torrance, CA, USA) and snap-frozen. For analysis, 4-5 lm tissue sections were stained with haematoxylin and eosin (H&E) by standard technique. The inflammatory lesions were graded histologically using the focus score (number of focuses per 4 mm 2 of each section; one focus was defined as > 50 mononuclear cells accumulation around the salivary gland ducts). Histological evaluation was performed in a blinded manner.
Stimulation of splenocytes and lymph node cell cultures with M3R peptides
At day 45 after splenocyte transfer, splenocytes and cervical lymph nodes (cLN) were isolated from M3R -/-!Rag-1 -/-mice. These cells (2Á0 3 10 5 cells/well) were cultured in RPMI-1640 medium (Sigma-Aldrich, St Louis, MO, USA) containing 10% fetal bovine serum (FBS), 100 units/ml of penicillin and 100 lg/ml of streptomycin, with or without mixture of six M3R extracellular peptides (5 lg/ml each) (M3R peptide mixture) in 96-well round-bottomed plates (Nunc, Rochester, NY, USA). After 72 h culture, IFN-g and IL-17 concentrations in the culture supernatant were measured using the Duoset enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions.
Criss-cross co-cultures using CD4
1 T cells and CD11c
1 cells under stimulation with M3R peptide
To determine the suppressive effects of A213 on CD4 1 T cells and CD11c 1 cells at day 20 after the first immunization, the two types of cells were isolated from the spleen of immunized M3R
-/-mice treated with A213 or PBS by magnetic activated cell sorting (MACS)-positive selection using anti-CD4 microbeads or anti-CD11c microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). CD11c 1 cells were treated with mitomycin C (50 lg/ml) and used as antigenpresenting cells (APCs). CD4
1 T cells and CD11c 1 cells obtained from M3R -/-mice treated with A213 or PBS were criss-cross co-cultured in RPMI-1640 medium under stimulation with M3R peptide mixture (5 lg/ml each) at a ratio of 5 : 1 (CD4 T cells: 1Á5 3 10 5 cells/well, CD11c 1 cells: 0Á3 3 10 5 cells/well) in 96-well round-bottomed plates (Nunc). After 72 h of co-culture, the amounts of IFN-g and IL-17 were measured in the culture supernatants using the Duoset ELISA kit (R&D Systems).
In-vitro functional analysis of A213 for M3R-specific cytokine production
Splenocytes or CD4
1 T cells obtained from immunized M3R -/-mice on day 20 after the first immunization were cultured with or without various concentrations of A213 (0Á04, 0Á2, 1 or 5 lM) under stimulation with M3R peptide mixture (5 lg/ml each). After 72 h of culture, the amounts of IFN-g and IL-17 were measured in the culture supernatants using the Duoset ELISA kit (R&D Systems).
Effects of A213 on the induction of Th1, Th17 and Th2 cell differentiation in vitro
CD4
1 cells obtained from the spleens of naive wild-type (WT) mice were isolated by positive selection using the MACS system with anti-CD4 mAb (Miltenyi Biotec). The CD4 1 T cells were stimulated for 4 days with plate-bound anti-CD3 (2 lg/ml) and soluble anti-CD28 (1 lg/ml) in the presence of recombinant mouse IL-12 (rmIL-12) (1 ng/ ml; BioLegend, San Diego, CA, USA) and anti-mouse IL-4 antibody (10 lg/ml; BioLegend) (induction of Th1 cells) or rmIL-6 (30 ng/ml; eBioscience, San Diego, CA, USA), recombinant human transforming growth factor (TGF)-b1 (rhTGF-b1) (1 ng/ml; R&D Systems), anti-mouse IFN-g antibody (10 lg/ml, BioLegend) and anti-mouse IL-4 antibody (10 lg/ml) (induction of Th17 cells) in complete RPMI-1640 medium containing 10% FBS, 100 units/ml of penicillin and 100 lg/ml of streptomycin. Moreover, the CD4 1 T cells were stimulated for 3 days with plate-bound anti-CD3 (2 lg/ml) and soluble anti-CD28 (1 lg/ml) in the presence of rmIL-4 (50 ng/ml; BioLegend), rhIL-2 (100 U/ml; Biovision, Milpitas, CA, USA) and anti-mouse IFNg antibody (10 lg/ml; BioLegend) in complete RPMI-1640 medium containing 10% FBS, 100 units/ml of penicillin and 100 lg/ml of streptomycin, and then half the medium was changed to that containing rmIL-4 (50 ng/ml; BioLegend), rhIL-2 (100 U/ml; Biovision) and anti-mouse IFN-g antibody (10 lg/ml; BioLegend) for 3 more days' culture (induction of Th2 cells). GolgiStop (BD Pharmingen, San Diego, CA, USA), Phorbol myristate acetate (PMA) and ionomycin were added during the last 4 h of each culture. The regulatory T cell (T reg ) cell staining kit (eBioscience) was used to stain Th1 and Th17 cells according to the protocol provided by the manufacturer using anti-RORgt-APC (eBioscience), anti-T-bet-phycoerythrin (PE) (eBioscience), anti-IL-17-PE-cyanin 7 (Cy7) (BioLegend) and anti-IFN-g-fluorescein isothiocyanate (FITC) (BioLegend). 
Statistical analysis
Data are expressed at mean 6 standard error of the mean (s.e.m.) or mean 6 standard deviation (s.d.). Differences between groups were examined for statistical significance using Student's t-test or Kruskal-Wallis test. P-values less than 0Á05 were considered significant.
Results
Pretransfer treatment with A213
Pretransfer A213 treatment of MIS mice maintained salivary secretion at day 45 after transfer, relative to day 0 (Fig.  2a) , but there was no significant difference in saliva secretion or body weight between the A213-and PBS-treated groups (Fig. 2a) . Mononuclear cell infiltration in salivary glands was observed in both MIS pretransfer treated with A213 and PBS (Fig. 2b) . The focus score of sialadenitis in MIS pretransfer treated with A213 tended to be lower than in those treated with PBS, albeit insignificantly (Fig. 2c) . M3R-specific IFN-g and IL-17 production by splenocytes and LN cells from M3R -/-!Rag-1 -/-mice pretransfer treated with A213 were similar to those treated with PBS (Fig. 2d,e) . These findings suggest that pretransfer treatment with A213 had no effects on salivary function and sialadenitis in mice with MIS.
Pretransfer treatment with A213 inhibits cytokine production from M3R-reactive CD4 1 T cells
We compared cytokine production by splenocytes in response to stimulation with M3R peptides between immunized M3R -/-mice treated with A213 and PBS. IL-17 production from splenocytes stimulated with M3R peptides was significantly lower in immunized M3R
-/-mice treated with A213 compared with PBS-treated mice (P < 0Á05) (Fig. 3a,  right panel) . Similarly, IFN-g production against M3R peptides stimulation was also significantly lower in A213-treated mice than PBS-treated mice (P < 0Á05) (Fig. 3a, left panel) .
In the next step, we performed criss-cross co-culture assays using CD4
1 T cells and stimulation with M3R peptides to clarify whether the suppressive action of A213 on cytokine production was based on CD4 1 T cells or CD11c 1 cells. M3R-specific production of both IFN-g and IL-17 from CD4 1 T cells was significantly less in A213-treated M3R -/-mice compared with PBStreated mice (P < 0Á05), regardless of CD11c 1 cell status (Fig. 3b,c) . These results suggest that A213 suppresses both M3R-reactive Th1 and Th17 cells rather than CD11c 1 cells.
Post-transfer treatment with A213
Saliva secretion was examined before and after post-transfer treatment with A213 (Fig. 1c, protocol B , post-transfer treatment). The secretion was conserved significantly at day 45 post-transfer compared with PBS (P < 0Á05, Fig. 4a ). Infiltration of mononuclear cells was observed in salivary glands in both MIS post-transfer treated with A213 and PBS (Fig. 4b) . The sialadenitis focus score was significantly lower in posttransfer A213-treated MIS compared with PBS (P < 0Á05) (Fig. 4c) . M3R-specific IFN-g and IL-17 production levels by splenocytes and lymph node cells from post-transfer A213-treated M3R
-/-!Rag-1 -/-mice were suppressed significantly compared with PBS-treated mice (P < 0Á05, Fig. 4d,e) . These findings suggest that post-transfer treatment of MIS mice with A213 abrogated the decrease in salivary secretion and sialadenitis via suppression of both M3R-reactive Th1 and Th17 cells.
Effects of A213 on M3R-specific cytokines production and induction of Th1, Th17 and Th2 cell differentiation in vitro A213 suppressed M3R-specific IL-17 production significantly from splenocytes obtained from immunized M3R
-/-mice in vitro (P < 0Á05, Fig. 5a, right panel) . Interestingly, A213 also suppressed M3R-specific IFN-g production significantly (P < 0Á05, Fig. 5a , left panel), similar to its effects in vivo. To test whether the inhibitory effects of A213 on cytokine production and cell differentiation are dosedependent, cultured splenocytes and CD4 1 T cells from immunized M3R
-/-mice under M3R peptide stimulation were treated with different concentrations of A213 (0, 0Á04, 0Á2, 1 or 5 lM). The results showed that A213 repressed IL-17 production in a dose-dependent manner (Fig. 5b,c, right  panel) , whereas IFN-g production under M3R peptides stimulation was decreased significantly only by the highest concentration of A213 (5 lM) (Fig. 5b,c, left panel) .
In addition, CD4 1 T cells isolated from naive WT mice were cultured in the presence of IL-12 and anti-IL-4 monoclonal antibodies (mAb) (for induction of Th1 cells), IL-6, In Th1 and Th2 conditions, cell viability, T-bet and GATA3 expression levels, and IFN-g and IL-4 production was not affected, even at high concentrations of A213 (Fig. 6a,c) . Conversely, IL-17 expression from Th17-differentiated CD4 1 T cells were clearly suppressed by A213 in a dose-dependent manner (Fig. 6b, right panel) , while cell viability and RORgt expression levels were not affected by A213 at any concentration (Fig. 6b, left and middle panels) . These results suggested that A213 suppressed not only M3R-reactive Th17 cells but also M3R-reactive Th1 cells at high concentrations, whereas A213 suppressed only IL-17 production from Th17-differentiated CD4 1 T cells and A213 did not affect Th1 and Th2 differentiation in vitro.
Discussion
Due to the known roles of RORgt in autoimmunity, we designed the present study to test whether RORgt targeting is a suitable therapeutic option for the treatment of SS [6] . The results showed the efficacy of RORgt-specific antagonist, A213, in MIS. In a series of studies, Iizuka et al. [20, 21] demonstrated that M3R-reactive Th17 and Th1 cells contributed to the pathogenesis of autoimmune sialadenitis, highlighting the potential roles of IL-17 and IFN-g in the pathogenesis of SS. Furthermore, IL-17 and IFN-g deficiencies in M3R
-/-!Rag-1 -/-mice reduced sialadenitis and improved salivary dysfunction [20, 21] . Th17 cells are linked to a number of organ-specific autoimmune diseases, including psoriasis, and as Sano et al. described the utility of A213 in a murine psoriasis model (personal communication), we felt that this approach was feasible to address specifically the roles of Th17 cells in SS. A213 suppressed immune-mediated pathology, including Th1 and Th17 cells both in vitro and in vivo, and inhibited salivary dysfunction and sialadenitis in MIS successfully through the suppression of IFN-g and IL-17 production. Our data are consistent with these observations, as we demonstrated that posttransfer treatment with A213 reduced the severity of sialadenitis. In contrast to post-transfer treatment with A213, pretransfer treatment with A213 could not suppress sialadenitis in MIS significantly. Both M3R-reactive Th1 and Th17 cells, which contribute essentially to the induction of MIS in transferred Rag-1 -/-mice, could be generated by immunization of M3R -/-mice with M3R peptide mixtures, as described in our previous reports [13, 20, 21] . Thus, we consider that these M3R-reactive Th1 and Th17 cells could be the target population in this pretransfer treatment with A213. We speculated that suppressed M3R-reactive Th1 and Th17 cells by pretransfer treatment with A213 could be reactivated after transfer into Rag-1 -/-mice in which M3R antigens existed. In fact, M3R-specific IFN-g and IL-17 production by splenocytes and LN cells from M3R -/-!Rag-1 -/-mice pretransfer treated with A213 were similar to those treated with PBS.
What is the mechanism of suppressive action of A213 on IFN-g expression on M3R-reactive CD4 1 T cells? Although our results did not identify the exact mechanism of low IFN-g concentrations, we propose the following three possibilities. First, it is conceivable that A213 inhibits the conversion of Th17 cells into Th1 cells. Th17 cells transform into Th1 cells in the presence of inflammation, including C57BL/6J mice [23] . As reported by Lee et al. [24] , inoculation of Th17 cells into Rag-1 -/-mice induced severe colitis.
A large proportion of transferred cells lost the expression of IL-17 and became IFN-g producers, demonstrating the plasticity of the Th17 lineage in vivo. Consistent with the in-vivo findings, Th17 cells either retained high expression of IL-17 or expressed variable levels of IL-17 and IFN-g in vitro [24, 25] . IFN-g-and IL-17-producing double-positive cells have also been identified in primary SS [26] . We did not see any substantial inhibition of transformation in vitro using A213. However, this is not surprising, because the invitro conditions rarely mimic the true in-vivo inflammatory conditions, and as-yet unknown factors may also be involved in this process (data not shown). Secondly, the reduced IFN-g expression on Th1 cells might be RORgtdependent, indicating the indirect effects of RORgt on IFN-g expression. Considering that RORgt is expressed ubiquitously throughout the body, it is possible that A213 directly affected the development of Th1 and Th17 cells. RORgt is expressed in innate lymphoid cells, and inhibition of RORgt expression could result in decreased cytokine expression in vivo [27] [28] [29] [30] . Thirdly, our results revealed that A213 suppressed not only M3R-reactive Th17 cells but also M3R-reactive Th1 cells at high concentrations, whereas A213 suppressed only IL-17 production from Th17-differentiated CD4 1 T cells and A213 did not affect Th1 and Th2 differentiation in vitro. Thus, it is indicated that A213 inhibits both antigen-specific Th17 and Th1 responses in vivo and especially at high concentrations in vitro, notwithstanding that A213 suppresses IL-17 production specifically from Th17-differentiated CD4 1 T cells in vitro, without any effect on cell viability, expression levels of transcriptional factors such as RORgt, T-bet and GATA3 of Th17-, Th1-and Th2-differentiated CD4
1 T cells and IFN-g from Th1-differentiated CD4
1 T cells and IL-4 from Th2-differentiated CD4 1 T cells. Collectively, A213 might represent different modes of action between antigenspecific processes in vivo and vitro, and cytokinedependent T cell differentiation in vitro. Although the above scenarios should be investigated in more detail in future, none of these factors alone seems sufficient to explain the low IFN-g level in post-transfer-treated mice, because no significant difference was observed in IFN-g concentration in pretransfer-treated mice.
These data suggest that targeting RORgt provided more protection than merely targeting a single cytokine. Support for this hypothesis comes from treatment using corticosteroids [3, [31] [32] [33] [34] [35] [36] , conventional immunosuppressants [3, [31] [32] [33] [34] [35] [36] and certain biologicals, such as rituximab [3, [31] [32] [33] [34] [35] [36] [37] [38] . These drugs are effective for extra-glandular manifestations of SS, but their usefulness against glandular manifestations has not been established. In fact, the use of corticosteroids and conventional immunosuppressants is associated with several well-known adverse effects, such as pneumonia, meningitis, fever, skin itching or rash [3, [31] [32] [33] [34] [35] [36] . A213 has a clear treatment target, RORgt, and had no obvious adverse effects, such as weight reduction, in pre-or post-transfer-treated mice (data not shown). These findings suggest that A213 can be potentially useful in the treatment of SS. Treatment with biologicals also imposes a great burden on patients in relation to the need for intravenous drip and subcutaneous injection [3, [31] [32] [33] [34] [35] [36] . A213 was extremely effective when administered orally in post-transfer-treated mice, suggesting that it may be more convenient for administration compared with biologicals.
In conclusion, we have demonstrated that regulation of RORgt activity improves MIS outcome, suggesting that small-molecule inhibitors may prove beneficial for treatment of sialadenitis, as they target many arms of SS pathogenesis.
